Logo
x

Search

Subscribe Now

Neurodegenerative Disease

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

  • October 27, 2021
BMS Exercised Its Option to License Evotec's EVT8683 for the Treatment of Neurodegenerative Disease

BMS Exercised Its Option to License Evotec's EVT8683 for the Treatment of Neurodegenerative Disease

  • September 2, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.